Is Neurosense Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Neurosense Therapeutics Ltd (NRSN) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Neurosense Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neurosense Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Neurosense Therapeutics Ltd?

Muslim investors may consider investing in Neurosense Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Neurosense Therapeutics Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Neurosense Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Neurosense Therapeutics Ltd updated?

The Shariah compliance status of Neurosense Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Neurosense Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Neurosense Therapeutics Ltd?

You can check the latest Shariah compliance status of Neurosense Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NRSN Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 30, 2026

Report Source: 2025 Annual Report

Neurosense Therapeutics Ltd. Stock Analysis NRSN

United States Health Care Nano Cap Report: 2025 Annual

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Key Statistics of Neurosense Therapeutics Ltd (NRSN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.82$0.86

Today's Open

$0.85

Volume

43.38K

P/E Ratio (TTM)

52 Week Range

$0.63$2.60

Market Cap

33.58M

Avg. Volume

144.04K

Dividend Yield

Financial Metrics & Statements of Neurosense Therapeutics Ltd (NRSN)

FAQ's for Neurosense Therapeutics Ltd (NRSN)

According to Musaffa’s Shariah screening methodology, Neurosense Therapeutics Ltd (NRSN) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.